Astex Pharmaceuticals to Participate on Epigenetics Panel at Rodman & Renshaw Conference

| Source: Astex Pharmaceuticals, Inc.

DUBLIN, Calif., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that James S.J. Manuso, PhD, chairman and chief executive officer, will participate in a Rodman & Renshaw Global Investment Conference panel discussion titled, "Epigenetics: The Silent Revolution in Oncology Research" on Monday, September 10th at 9:15 a.m. ET in New York.

Key opinion leader Jean-Pierre Issa, MD, director, Fels Institute for Cancer Research and Molecular Biology, Temple University will also be speaking on the panel, amongst others.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit

The Astex Pharmaceuticals, Inc. logo is available at

Timothy L. Enns
Astex Pharmaceuticals, Inc.
Senior Vice President
Corporate Communications & Marketing
Tel:  +1 (925) 560-2810

Susanna Chau
Astex Pharmaceuticals, Inc.
Investor Relations
Tel:  +1 (925) 560-2845

Alan Roemer
The Trout Group
Managing Director
Tel:  +1 (646) 378-2945

Kari Watson
MacDougall Biomedical Communications
Senior Vice President
Tel: +1 (781) 235-3060